Clinical outcomes of hemostatic interventions in patients with traumatic injury: A systematic review of randomized controlled trials.

J Trauma Acute Care SurgJun 15, 2026 (epub)
Clinical ResearchGeneral SurgeryEmergency Medicine

James Winearls, Elham Ashrafi, Erica Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 110 randomized controlled trials (RCTs) evaluating hemostatic interventions in trauma patients. The study found that mortality was the primary outcome in 56.4% of trials, with 36.4% reporting a statistically significant difference. The review highlights significant variability in outcome reporting, particularly regarding patient-centered outcomes.

Key findings

  • Mortality was the primary outcome in 56.4% of the included studies.
  • 36.4% of trials reported a statistically significant difference in mortality outcomes.
  • Patient-centered outcomes like quality of life were infrequently assessed, with only 7.3% reporting.
  • Most trials (88.2%) were parallel-group RCTs with a median sample size of 314 participants.

Why it matters

Understanding the variability in outcome reporting for hemostatic interventions is crucial for clinicians to interpret trial results effectively. Standardizing outcomes could enhance the quality of evidence and inform better clinical practices in trauma care.

Source

PubMed · PMID 42296330

Published in J Trauma Acute Care Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.